Results 51 to 60 of about 14,860 (180)

Personalizing smoking cessation pharmacotherapy using neuroaffective reactivity profiles: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims By assessing neuroaffective response to motivationally relevant cues before a quit attempt, we have shown that smokers who attribute greater incentive salience to cigarette‐related cues than non‐cigarette‐related rewards (Sign‐trackers, ST) benefit more from varenicline compared with smokers with the opposite neuroaffective
Francesco Versace, Charles E. Green, Yong Cui, Jason D. Robinson, Menton M. Deweese, Jennifer A. Minnix, George Kypriotakis, Seokhun Kim, Maher Karam‐Hage, Paul M. Cinciripini   +9 more
wiley   +1 more source

Prospective cohort study of the effectiveness of varenicline versus nicotine replacement therapy for smoking cessation in the "real world" [PDF]

, 2014
It is important to know the comparative effectiveness of varenicline and nicotine replacement therapy (NRT) for smoking cessation when prescribed under routine circumstances and in the general population. Previous estimates relied on cross-sectional data.
Brown, J, Kotz, D, West, R
core   +1 more source

Determining the impact of cannabis use on tobacco cessation: Results from a prospective non‐randomized tobacco treatment trial

Addiction, EarlyView.
Abstract Background and aims Tobacco‐cannabis co‐use is associated with increased psychosocial and health harms; however, the treatment literature assessing the impact of co‐use has been mixed and suffers from critical limitations. To date, no prospective studies have evaluated the degree to which cannabis co‐use affects tobacco cessation, nor are ...
Erin A. McClure, Nathaniel Baker, Rachel L. Tomko, Kyle J. Walters, Elizabeth Chapman, Matthew J. Carpenter, Kevin M. Gray   +6 more
wiley   +1 more source

Smoking cessation in severe mental ill health : what works? an updated systematic review and meta-analysis [PDF]

, 2017
BACKGROUND: People with severe mental ill health are more likely to smoke than those in the general population. It is therefore important that effective smoking cessation strategies are used to help people with severe mental ill health to stop smoking ...
A Baker, A Baker, AE Evins, AE Evins, AE Evins, AE Evins, AH Weinberger, AL Baker, B O'Brien, BS Wu, C Bullen, C McDonald, E Ratschen, E Weiner, E Weiner, Emily Peckham, Garry Tew, GW Dalack, HK Chen, J Hartmann-Boyce, JM Williams, JM Williams, JM Williams, JW Tidey, KN Chengappa, KR Fontaine, L Banham, Liz Cook, ML Steinberg, ML Steinberg, Q Wu, RC Smith, RM Anthenelli, S Brown, S Fatemi, S Gilbody, Sally Brabyn, SE Adkison, Simon Gilbody, SM Gallagher, TP George, TP George, TP George, VC Wing   +43 more
core   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Nicotine receptor partial agonists for smoking cessation

São Paulo Medical Journal
BACKGROUND: Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist)
Kate Cahill, Lindsay F. Stead, Tim Lancaster, Igor Bastos Polonio   +3 more
doaj   +1 more source

Varenicline versus nicotine replacement therapy for long-term smoking cessation: an observational study using the Clinical Practice Research Datalink

Health Technology Assessment, 2020
Background: Smoking is the leading avoidable cause of illness and premature mortality. The first-line treatments for smoking cessation are nicotine replacement therapy and varenicline.
Neil M Davies, Amy E Taylor, Gemma MJ Taylor, Taha Itani, Tim Jones, Richard M Martin, Marcus R Munafò, Frank Windmeijer, Kyla H Thomas   +8 more
doaj   +1 more source

Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics. [PDF]

, 2019
Mood disorders are highly prevalent and are the leading cause of disability worldwide. The neurobiological mechanisms underlying depression remain poorly understood, although theories regarding dysfunction within various neurotransmitter systems have ...
Dulawa, Stephanie C, Janowsky, David S
core  

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland

Acta Ophthalmologica, EarlyView.
Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen, Jari Haukka, Tuomas Lilius, Sirpa Loukovaara   +3 more
wiley   +1 more source

What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation

Health Technology Assessment, 2014
Background: Tobacco smoking is one of the leading causes of deaths worldwide. Nearly one-fifth of adults in the UK regularly smoke cigarettes. The ill-health associated with smoking costs the NHS over £3B every year.
Joanna Leaviss, William Sullivan, Shijie Ren, Emma Everson-Hock, Matt Stevenson, John W Stevens, Mark Strong, Anna Cantrell   +7 more
doaj   +1 more source